The Translational Oncology Partnership Program leads a comprehensive research initiative focused on understanding therapeutic resistance and genomic heterogeneity in various types of cancer via multimodal studies, including DNA, protein, RNA, and imaging.
The initiative supports a wide portfolio of biospecimen-based and data-focused protocols including tissue and liquid biopsy studies, which enable detailed genomic analyses across disease stages and treatment contexts.
In parallel, the program leverages clinical and molecular data through collaborations with internal computational teams and industry partners to drive data-driven discovery in oncology.
Some of the projects we support include:
- A dedicated study led by Pedram Razavi, MD, PhD, includes multimodal prediction efforts that integrate clinical and genomic data to forecast treatment outcomes. Recent work includes studies on identifying the resistance mechanisms and outcome prediction for patients with breast cancer.
- iBRAIN: Integrated Biomarker evaluation with RAdiation for Intracranial Neoplasms is a research initiative led by Luke Pike, MD, DPhil, that is designed to identify unique genomic and epigenomic features of brain metastases using multimodal approaches.
- MSK Pharmaceutical Partnership Initiative led by Ross Levine, MD, and Paul Sabbatini, MD, together with MSK’s Translational Research Administration and Clinical Research Administration. This initiative hosts a series of on-site meetings with colleagues from industry, wherein we invite research and clinical leadership teams to MSK for strategic discussions. This is done in partnership with our Office of Entrepreneurship and Commercialization.